MapLight Therapeutics, Inc. (MPLT) Stock Analysis

MapLight Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Thu, August 13, 2026 at 8:05 PM UTC 3 min read

MapLight Therapeutics reported its second quarter 2026 financial results, highlighting significant advancements in its clinical programs and a strong cash position. The company’s progress in developing innovative therapies could enhance its market position and attract investor interest. This update is crucial for investors as it reflects the company's operational health and potential for future growth in the biotech sector.

Read full article →

MPLT Stock Plunges 73% — Wipes Out Over $1B In Market Cap After Trial Miss On Once-Daily Dose

Mon, July 27, 2026 at 11:08 PM UTC 3 min read

MPLT's stock plummeted 73%, resulting in a loss of over $1 billion in market capitalization, following disappointing trial results for its once-daily dosing regimen. This significant decline raises concerns for investors regarding the company's future prospects and potential revenue streams. The trial miss may hinder MPLT's ability to compete effectively in the market, prompting investors to reassess their positions in light of the increased uncertainty surrounding the company's product pipeline.

Read full article →